HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Coyle, P. K. Search for Related Content PubMed PubMed Citation Articles by Coyle, P. K.

Early treatment of multiple sclerosis to prevent neurologic damage

From the MS Comprehensive Care Center, Stony Brook University Medical Center, Stony Brook, New York.

Address correspondence and reprint requests to Dr. Patricia K. Coyle, Comprehensive Care Center, SUNY at Stony Brook, HSC, T-12, NM020, Stony Brook, NY 11794 pcoyle{at}notes.cc.sunysb.edu

Multiple sclerosis (MS) involves ongoing accumulating CNS damage. Precisely which environmental factors trigger onset and progression of the disease are not known. However, clinical trials indicate benefits from early use of disease-modifying therapies (DMTs). All the completed clinically isolated syndrome trials (CHAMPS, ETOMS, BENEFIT, PRECISE) reported significant suppression of subsequent relapse and MRI lesion formation from use of DMT at the first relapse. This article reviews data on early treatment. Such an approach requires the ability to recognize clinically isolated syndrome features that indicate a diagnosis of MS.

Disclosure: Sources of Funding for Research: Bayer HealthCare Pharmaceuticals; EMD Serono, Inc.; Teva Neuroscience, Inc. Consulting Agreements: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Pfizer Inc; Teva Neuroscience, Inc. Speakers’ Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Pfizer Inc; Teva Neuroscience, Inc.

Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.